Gambia
Tuberculosis profile
Population  2012 1.8 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.91 (0.36–1.7) 51 (20–96)
Mortality (HIV+TB only) 0.3 (0.25–0.33) 17 (14–19)
Prevalence  (includes HIV+TB) 8.8 (4.4–15) 490 (245–819)
Incidence  (includes HIV+TB) 5.1 (4.2–6) 284 (234–337)
Incidence (HIV+TB only) 0.76 (0.63–0.9) 42 (35–50)
Case detection, all forms (%) 46 (39–56)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 429 (64) Relapse 92 (63)
Smear-negative 643 (29) Treatment after failure 28 (19)
Smear-unknown / not done 0 (0) Treatment after default 26 (18)
Extrapulmonary 169 (8) Other 0 (0)
Other 0 (0)      
Total new 2 241   Total retreatment 146  
           
Other (history unknown)          
Total new and relapse 2 333   Total cases notified 2 387  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.2    
Age < 15 23    
Laboratories 2012
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 2.8
Drug susceptibility testing (per 5 million population) 2.8
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment 78  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 859 (78)
HIV-positive TB patients 302 (16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 294 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 146 (48)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.48 (0.01–2.6) 0 (0–18)
MDR-TB cases among notified pulmonary
TB cases
10 (0–54) 0 (0–26)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-16 Data: www.who.int/tb/data